Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Cristina Buges"'
Autor:
Sara Cabrero-de las Heras, Xavier Hernández-Yagüe, Andrea González, Ferran Losa, Gemma Soler, Cristina Bugés, Iosune Baraibar, Anna Esteve, Miguel Ángel Pardo-Cea, Anne Hansen Ree, Neus Martínez-Bosch, Maria Nieva, Eva Musulén, Sebastian Meltzer, Tania Lobato, Carla Vendrell-Ayats, Cristina Queralt, Pilar Navarro, Clara Montagut, Ferran Grau-Leal, David Camacho, Raquel Legido, Núria Mulet-Margalef, Eva Martínez-Balibrea
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 176, Iss , Pp 116857- (2024)
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-l
Externí odkaz:
https://doaj.org/article/9a44f4acd0ee417b9239aafcd72443e1
Publikováno v:
Clinical Colorectal Cancer. 21:71-79
In recent years, studies on the molecular typing of colorectal cancer have matured, and the V-raf murine sarcoma viral oncogene homolog B (BRAF) of the mitogen-activated protein kinase pathway has been shown to be an important effector molecule of th
Autor:
Monica Caro, Cinta Hierro, Ricard Mesia, Jose Luis Manzano, Cristina Buges, Laura Layos, Gabriela Antelo, Eduardo Baena, Juan Pablo Fernández
Publikováno v:
Drugs in Context
Drugs in Context, Vol 9, Pp 1-13 (2020)
Drugs in Context, Vol 9, Pp 1-13 (2020)
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumours, which can be classified into neuroendocrine tumours (NETs), neuroendocrine carcinomas (NECs) and mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs). To date, there is
Autor:
Sara Bystrup, Manel Esteller, Vicenç Ruiz de Porras, Jose Luis Manzano, Catia Moutinho, Anna Martínez-Cardús, Cristina Buges, Albert Abad, Laura Layos, Alba Ginés, Eva Martinez-Balibrea
Publikováno v:
Molecular Cancer Therapeutics. 14:1767-1776
Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for t
Autor:
Sara Bystrup, Lauro Sumoy, Laura Layos, Eva Martinez-Balibrea, Vicenç Ruiz de Porras, Chinenye Iwuji, Jose Luis Manzano, Raquel Pluvinet, Albert Abad, Anna Martínez-Cardús, Mark I. James, Lynne M. Howells, Cristina Buges
Publikováno v:
Scientific Reports
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
This study was funded by the ISCIII grant, project n° PI1202228 and Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya. SGR-PREDIVHICO. This work was done under the framework of the doctorate in Medicine from the Universitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::722b2c0b6545f1501a9997fae50db82d
http://hdl.handle.net/2445/126854
http://hdl.handle.net/2445/126854
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11403 (2023)
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as p
Externí odkaz:
https://doaj.org/article/c4273883658f4a7083f3fb2081e5498d
Autor:
Eva Musulen, Eva Martinez-Balibrea, Cristina Buges, V. Ruiz de Porras, J.L. Subirats, Victor Moreno, Sara Bystrup, S. Cabrero-De las Heras, Jose Luis Manzano, Laura Layos
Publikováno v:
European Journal of Cancer. 61:S204
Autor:
Anna Martínez-Cardús, Maria de los Llanos Gil, Laia Vilà, Laura Layos, Cristina Buges, Eva Martinez-Balibrea, Jose Luis Manzano
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Patients with advanced melanoma have traditionally had very poor prognosis. However, since 2011 better understanding of the biology and epidemiology of this disease has revolutionized its treatment, with newer therapies becoming available. These newe
Autor:
Ignacio Delgado, Javier Sastre, Purificación Martínez, Manuel Valladares, Ana Maria Lopez, Jose Ignacio Martin Valades, Guillermo Alfonso Quintero Aldana, O. Donnay, Jose Carlos Mendez, Jaime Feliu, Cristina Buges, Ruth Vera, Isabela Diaz De Corcuera Frutos, Jose Miguel Martin Martinez, Julia Alcaide, Nieves del Pozo, David Marrupe, T. García, A. Juarez, Mercedes Salgado Fernández
Publikováno v:
Journal of Clinical Oncology. 34:689-689
689 Background: InVELOUR trial the addition of aflibercept to FOLFIRI regimen, demonstrated a statistically significant overall survival improvement in mCRC patients (pts) who progressed on or after a prior oxaliplatin based regimen with or without b
Autor:
Margarita Majem, Cristina Buges, Enriqueta Felip, Clara Mayo, Radj Gervais, Bartomeu Massuti, Enric Carcereny, Alain Vergnenegre, Mariacarmela Santarpia, Filippo de Marinis, Joaquim Bosch, Felipe Cardenal, Ana Drozdowskyj, Jordi Bertran-Alamillo, Miquel Taron, Trever G. Bivona, Miguel Angel Molina-Vila, Javier de Castro, Teresa Moran, Rafael Rosell
7522 Background: When EGFR compound mutants (exon 19 deletions or L858R plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer overall survival (OS) (Oxnard et al. CCR 2011). The H1975 cell line, harboring L858
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30c8fca98280103c095da3ef9fd9ecea
http://hdl.handle.net/11570/3023579
http://hdl.handle.net/11570/3023579